Using an insulin dosing calculator for better blood sugar management in hospitalized patients with type 2 diabetes
Feasibility Trial Using an Insulin Dosing Calculator for Patients With Type 2 Diabetes Mellitus on Hospital Admission
This study is testing whether using a special insulin calculator can help hospitalized patients with type 2 diabetes manage their blood sugar better than traditional methods.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 85 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Washington Academic / other |
| Locations | 3 sites (Seattle, Washington and 2 other locations) |
| Trial ID | NCT06206525 on ClinicalTrials.gov |
What this trial studies
This feasibility trial aims to evaluate the effectiveness of a novel insulin dosing calculator in managing blood glucose levels for patients with type 2 diabetes mellitus upon hospital admission. Participants will receive initial insulin doses calculated by the tool, while their ongoing care will follow standard protocols. The study will compare outcomes of these patients with those receiving traditional insulin dosing methods to assess the calculator's impact on preventing excessive hypoglycemia and reducing hyperglycemia.
Who should consider this trial
Good fit: Ideal candidates include patients admitted to the University of Washington Medical Centers with a history of type 2 diabetes who are already on insulin therapy.
Not a fit: Patients who are critically ill, undergoing elective surgery, or unable to eat may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved blood glucose control and reduced complications for hospitalized patients with type 2 diabetes.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving diabetes management in hospital settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who are admitted to University of Washington Medical Centers * With history of type 2 and/or steroid-induced diabetes mellitus * Receiving insulin therapy prior to admission Exclusion Criteria: * Patients who are admitted to ICU or obstetrics ward * Patients who are admitted for elective surgery or procedure * Patients who present with diabetic ketone acidosis, hyperosmolar hyperglycemic state or require intravenous insulin infusion * Patients who have no meal intake for 24 hours prior to admission, or planned nothing per oral (NPO) during the first 24 hours after admission * Patients who report low appetite (25% or less) on admission or have a significantly decreased level of consciousness that they unlikely eat right after admission * Patients who receive enteral feeding after admission
Where this trial is running
Seattle, Washington and 2 other locations
- Harborview Medical Center — Seattle, Washington, United States (Recruiting)
- UW Medical Center - Northwest — Seattle, Washington, United States (Recruiting)
- UW Medical Center - Montlake — Seattle, Washington, United States (Recruiting)
Study contacts
- Principal investigator: Hou-Hsien Chiang, MD, PhD — University of Washington
- Study coordinator: Hou-Hsien Chiang, MD, PhD
- Email: htchiang@uw.edu
- Phone: 206-221-5705
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.